nanobodi
nb
also
call
camelid
heavychain
variabl
domain
vhh
singledomain
nanos
antibodi
deriv
variabl
fragment
camelid
shark
heavi
chainonli
antibodi
nb
contain
four
constant
region
name
framework
region
fr
three
connect
variabl
region
call
complementar
determin
region
cdr
fr
respons
maintain
structur
integr
nb
cdr
directli
bind
antigen
epitop
one
hand
nanomet
size
nm
nm
singl
domain
structur
nb
follow
advantag
antivir
agent
easili
express
bulk
product
robust
conveni
storag
transport
good
permeabl
tissu
hand
also
small
size
nb
follow
potenti
limit
antivir
agent
may
limit
bind
affin
antigen
may
clear
bodi
rel
quickli
upper
size
limit
protein
renal
clearanc
kda
nevertheless
use
nb
antivir
therapeut
agent
gain
clinic
accept
focu
overcom
potenti
limit
middl
east
respiratori
syndrom
coronaviru
merscov
first
identifi
june
continu
infect
human
led
least
confirm
case
death
fatal
rate
countri
http
wwwwhointemergenciesmerscoven
bat
dromedari
camel
like
natur
reservoir
transmiss
host
respect
merscov
wherea
cameltohuman
transmiss
merscov
account
human
infect
humantohuman
spread
merscov
also
occur
sporad
current
therapeut
agent
vaccin
approv
human
use
due
continu
threat
merscov
urgent
need
develop
highli
potent
costeffect
broadspectrum
antimerscov
therapeut
vaccin
potenti
largescal
industri
product
therapeut
antibodi
shown
effect
antivir
agent
receptorbind
domain
rbd
merscov
spike
protein
prime
target
therapeut
antibodi
merscov
protein
guid
viral
entri
host
cell
first
bind
host
receptor
dipeptidyl
peptidas
rbd
subunit
fuse
viral
host
membran
subunit
rbd
contain
receptorbind
motif
rbm
region
residu
directli
interact
previous
shown
rbdbase
vaccin
highli
immunogen
induc
product
potent
antimerscov
crossneutr
antibodi
moreov
discov
sever
rbdspecif
monoclon
antibodi
mab
strong
neutral
activ
lethal
merscov
infect
human
mice
rbdtarget
mab
current
develop
antimerscov
therapeut
experiment
anim
model
howev
widespread
use
convent
antibodi
limit
larg
size
high
product
cost
inconveni
storag
transport
poor
pharmacokinet
make
nb
attract
altern
tradit
mab
treat
merscov
infect
current
shown
whether
merscov
rbd
reliabl
trigger
product
nb
whether
produc
nb
overcom
potenti
limit
eg
low
bind
affin
rbd
rel
short
halflif
bodi
whether
produc
nb
demonstr
suffici
therapeut
efficaci
warrant
develop
clinic
set
immun
llama
recombin
merscov
rbd
protein
gener
novel
neutral
nb
also
construct
humanfcfus
version
investig
nb
rbdbind
capabl
neutral
mechan
crossneutr
activ
diverg
merscov
strain
halflif
protect
efficaci
lethal
merscov
infect
establish
mous
model
studi
reveal
efficaci
robust
broadspectrum
nb
produc
target
merscov
protein
rbd
hold
great
promis
potenti
antimerscov
therapeut
construct
nb
ie
vhh
librari
immun
llama
recombin
merscov
rbd
residu
strain
contain
ctermin
human
fc
tag
ie
rbdfc
isol
peripher
blood
mononuclear
cell
pbmc
immun
llama
four
round
biopan
screen
use
merscov
rbdfc
isol
posit
clone
highest
bind
affin
rbd
gene
encod
rbdspecif
nb
subclon
yeast
express
vector
construct
contain
ctermin
tag
contain
ctermin
human
fc
tag
nb
fig
express
yeast
cell
secret
cell
cultur
supernat
purifi
homogen
fig
left
estim
molecular
weight
kda
kda
sinc
latter
form
dimer
merscov
rbdspecif
nb
llama
sever
acut
respiratori
syndrom
coronaviru
sarscov
rbdspecif
mab
mice
recogn
antillama
antibodi
fig
right
thu
yeastexpress
nb
maintain
nativ
conform
antigen
character
function
examin
nb
interact
merscov
rbd
first
evalu
bind
nb
merscov
rbd
use
elisa
result
show
nb
bound
strongli
recombin
merscov
rbd
contain
ctermin
folden
tag
rbdfd
merscov
contain
ctermin
tag
dosedepend
manner
fig
second
determin
bind
affin
two
nb
merscov
rbd
use
surfac
plasmon
reson
spr
result
show
kd
rbdfc
nm
wherea
kd
nm
fig
third
carri
merscov
neutral
assay
result
show
nb
effici
neutral
infect
live
merscov
strain
vero
cell
measur
neutral
dose
fig
taken
togeth
nb
strongli
bound
merscov
rbd
neutral
merscov
infect
investig
mechan
underli
neutral
activ
nb
evalu
competit
nb
bind
merscov
rbd
first
carri
flow
cytometri
assay
recombin
merscov
rbd
interact
cellsurfaceexpress
presenc
absenc
recombin
nb
result
show
nb
significantli
block
bind
rbd
cellsurfac
dosedepend
manner
fig
b
neg
control
sarscovrbdspecif
mab
block
bind
merscov
rbd
cell
surfac
fig
b
second
carri
enzymelink
immunosorb
assay
elisa
recombin
merscov
rbd
recombin
interact
presenc
absenc
recombin
nb
result
show
nb
mab
block
bind
merscov
rbd
dosedepend
manner
moreov
compar
block
bind
effici
fig
data
reveal
nb
compet
bind
merscov
rbd
suggest
nbbind
site
site
overlap
merscov
rbd
map
bind
site
nb
merscov
rbd
perform
alanin
scan
surfac
merscov
rbd
detect
bind
nb
alaninecontain
rbd
mutant
result
show
demonstr
tight
bind
merscov
rbd
contain
singl
mutat
slightli
reduc
bind
rbd
contain
tripl
mutat
suggest
rbd
residu
play
signific
role
nb
bind
instead
singl
mutat
doubl
mutat
merscov
rbd
ablat
bind
rbd
fig
suggest
rbd
residu
play
import
role
nb
bind
investig
role
nb
bind
use
merscov
pseudoviru
entri
assay
neither
could
neutral
cell
entri
merscov
pseudoviru
bear
mutat
confirm
residu
critic
nb
bind
fig
examin
role
mutat
bind
carri
elisa
detect
bind
merscov
rbd
bear
mutat
result
show
mutat
significantli
reduc
bind
rbd
fig
overal
result
demonstr
nb
recogn
epitop
merscov
rbd
epitop
also
play
import
role
bind
therefor
nb
compet
region
merscov
rbd
mutat
region
reduc
bind
nb
investig
whether
nbrecogn
epitop
merscov
rbd
conform
linear
detect
bind
nb
merscov
rbd
conform
structur
disrupt
end
treat
merscov
rbd
reduc
agent
dithiothreitol
dtt
break
disulfid
bond
protein
perform
elisa
bind
nb
dtttreat
rbd
result
show
neither
bound
dtttreat
rbd
fig
control
nb
bound
untreat
rbd
high
affin
thu
nb
recogn
conform
epitop
rbd
understand
structur
mechan
underli
neutral
activ
nb
examin
competit
interact
among
nb
merscov
rbd
use
structur
model
fig
absenc
nb
merscov
rbd
bind
tightli
receptor
rbd
serv
key
residu
bind
interfac
fig
rbd
residu
form
critic
salt
bridg
interact
surround
key
rbd
residu
via
van
der
waal
contact
hydrogen
bond
fig
enabl
rbd
maintain
strong
bind
interact
nb
bind
tightli
rbd
region
abolish
bind
rbd
fig
investig
crossneutr
activ
nb
diverg
merscov
isol
perform
merscov
pseudoviru
entri
assay
presenc
nb
pseudovirus
encod
gene
variou
merscov
isol
differ
countri
saudi
arabia
qatar
south
korea
host
human
camel
time
period
merscov
strain
contain
mutat
rbd
result
show
nb
potent
neutral
cell
entri
merscov
pseudovirus
valu
rang
tabl
therefor
although
nb
develop
use
rbd
one
merscov
strain
broadspectrum
crossneutr
activ
exist
merscov
strain
well
potenti
futur
emerg
merscov
strain
evalu
vivo
halflif
nb
inject
nb
mice
collect
sera
mice
differ
time
interv
measur
bind
sera
recombin
merscov
use
elisa
result
show
sera
collect
mice
gradual
lost
bind
affin
merscov
complet
lost
bind
merscov
day
postinject
fig
comparison
demonstr
stabl
bind
recombin
merscov
day
postinject
fig
control
experi
sera
collect
pbsinject
mice
show
bind
recombin
merscov
fig
thu
compar
monomer
nb
fcfuse
nb
significantli
extend
vivo
halflif
like
due
dimer
structur
increas
molecular
weight
nb
kda
henc
may
slow
renal
clearanc
merscov
infect
wildtyp
mice
previous
develop
mice
suscept
anim
model
merscov
research
evalu
prophylact
efficaci
mice
inject
singl
dose
day
infect
lethal
dose
merscov
subsequ
monitor
weight
surviv
trastuzumab
antibodi
use
treat
breast
cancer
use
control
result
show
merscov
infect
mice
treat
surviv
rate
fig
steadi
weight
fig
comparison
mice
treat
trastuzumab
die
day
postinfect
weight
also
sharpli
decreas
start
day
postinfect
fig
evalu
therapeut
efficaci
mice
first
infect
merscov
treat
singledos
either
day
postinfect
result
show
mice
treat
day
postinfect
surviv
rate
steadi
weight
fig
addit
mice
treat
day
postinfect
also
surviv
rate
fig
although
weight
first
decreas
day
postinfect
rebound
day
postinfect
fig
comparison
mice
receiv
trastuzumab
die
day
infect
weight
continu
decreas
fig
c
overal
potent
prophylact
therapeut
efficaci
protect
suscept
anim
model
lethal
merscov
challeng
merscov
continu
infect
human
high
fatal
rate
camel
like
serv
transmiss
host
merscov
also
human
contact
camel
constant
continu
transmiss
merscov
camel
human
make
difficult
erad
merscov
human
popul
thu
efficaci
costeffect
broadspectrum
antimerscov
therapeut
agent
need
prevent
treat
merscov
infect
human
camel
nb
gain
accept
antivir
agent
small
size
good
tissu
permeabl
costeffect
product
storag
transport
howev
small
size
may
also
lead
rel
low
antigenbind
affin
quick
clearanc
host
bodi
studi
develop
novel
merscovtarget
nb
fcfuse
version
demonstr
great
promis
antimerscov
therapeut
agent
present
superior
characterist
common
nb
target
merscov
rbd
play
essenti
role
cell
entri
merscov
bind
receptor
nb
express
yeast
cell
high
puriti
yield
solubl
solut
properti
suggest
costeffect
product
easi
storag
conveni
transport
nb
potenti
commerci
applic
merscov
rbdtarget
nb
develop
also
demonstr
good
qualiti
compar
previous
report
merscov
rbdspecif
convent
igg
first
nb
bind
merscov
rbd
high
affin
kd
valu
bind
merscov
rbd
respect
kd
valu
rbdtarget
convent
igg
bind
merscov
rbd
rang
moreov
valu
neutral
merscov
strain
infect
cultur
cell
respect
valu
rbdspecif
convent
igg
neutral
variou
merscov
strain
rang
microgramsml
nanogramsml
thu
nb
develop
studi
convent
igg
report
previous
compar
merscov
rbdbind
affin
merscovneutr
activ
structur
comparison
convent
igg
nb
shown
antigenbind
site
igg
consist
pair
heavychain
lightchain
variabl
vhvl
domain
wherea
nb
lack
light
chain
henc
form
pair
vhvl
domain
instead
nb
extend
region
amino
acid
residu
longer
vh
convent
igg
averag
length
amino
acid
residu
moreov
nb
develop
contain
extend
enabl
nb
bind
antigen
higher
affin
furthermor
although
singledomain
nb
ie
small
clear
serum
rel
quickli
fcfuse
nb
ie
rel
increas
size
demonstr
extend
vivo
halflif
therefor
potenti
short
halflif
nb
overcom
ad
appropri
tag
nb
increas
halflif
overal
present
studi
shown
feasibl
overcom
potenti
limit
nb
merscov
rbdtarget
nb
potent
neutral
merscov
entri
host
cell
kd
valu
nb
merscov
rbd
significantli
lower
merscov
rbd
receptor
result
nb
outcompet
bind
merscov
rbd
therebi
block
bind
merscov
well
merscov
entri
host
cell
worth
note
rbd
merscov
trimer
frequent
undergo
conform
chang
switch
lie
receptorinaccess
conform
standingup
receptoraccess
conform
henc
context
viru
particl
rbd
part
protein
nb
would
need
bind
rbd
rbd
standingup
conform
importantli
nb
demonstr
strong
crossneutr
activ
variou
merscov
strain
isol
differ
host
human
camel
differ
time
point
merscov
circul
human
year
rel
high
strain
contain
mutat
consist
slightli
reduc
bind
affin
merscov
rbd
contain
mutat
fig
broad
neutral
spectrum
nb
result
bind
site
nb
merscov
rbd
locat
region
play
critic
role
bind
interestingli
sever
merscov
rbdspecif
convent
igg
also
bind
epitop
suggest
region
hot
spot
immun
recognit
although
mutat
region
elimin
bind
nb
merscov
rbd
henc
lead
viral
immun
evas
also
reduc
bind
merscov
rbd
receptor
henc
decreas
effici
viral
entri
thu
viral
immun
evas
inhibit
nb
mutat
costli
merscov
inde
residu
protein
rbd
highli
conserv
almost
natur
merscov
strain
publish
date
fig
therefor
merscovspecif
nb
potenti
develop
broadspectrum
antimerscov
therapeut
agent
despit
analysi
studi
examin
possibl
mutat
nbbind
region
sinc
atom
structur
merscov
rbd
complex
nb
still
unknown
thu
possibl
futur
escap
mutat
may
occur
residu
studi
cover
case
combin
current
nb
antibodi
target
region
variou
rbd
epitop
may
help
battl
emerg
immun
escap
merscov
strain
sum
merscovspecif
nb
develop
present
studi
possess
superior
qualiti
common
nb
small
size
costeffect
product
also
overcom
potenti
limit
nb
maintain
high
bind
affin
target
merscov
rbd
optim
halflif
moreov
recogn
function
import
region
merscov
rbd
render
viral
immun
evas
costli
time
make
good
candid
broadspectrum
antimerscov
therapeut
confirm
effect
nb
show
fcfuse
nb
complet
protect
anim
model
lethal
merscov
challeng
thu
nb
potenti
use
human
camel
prevent
treat
merscov
infect
either
host
also
block
cameltohuman
transmiss
merscov
overal
studi
prove
feasibl
develop
highli
effect
nb
antimerscov
therapeut
agent
point
strategi
preserv
advantag
nb
well
overcom
potenti
limit
nb
anim
studi
carri
strict
accord
recommend
guid
care
use
laboratori
anim
state
key
laboratori
pathogen
biosecur
beij
institut
microbiolog
epidemiolog
china
nation
institut
health
nih
anim
protocol
approv
iacuc
state
key
laboratori
pathogen
biosecur
beij
institut
microbiolog
epidemiolog
permit
bime
committe
ethic
anim
experi
new
york
blood
center
approv
construct
nb
ie
vhh
librari
screen
merscovrbdspecif
nb
perform
previous
describ
briefli
male
femal
alpaca
llama
paco
year
subcutan
immun
recombin
rbdfc
plu
freund
complet
adjuv
boost
three
time
immunogen
plu
freund
incomplet
adjuv
invivogen
blood
collect
day
last
immun
pbmc
isol
use
ficollpaqu
gradient
centrifug
ge
healthcar
total
rna
extract
trizol
reagent
invitrogen
cdna
synthes
revers
transcriptionpcr
rtpcr
use
transscript
cdna
synthesi
supermix
transgen
biotech
china
follow
pcr
amplif
ntermin
igg
heavychain
fragment
bp
use
forward
primer
vhhlf
revers
primer
vhh
gene
bp
amplifi
use
dna
fragment
templat
forward
primer
revers
primer
sfii
restrict
site
underlin
sfiidigest
vhh
dna
fragment
insert
phagemid
vector
bioview
shine
biotechnolog
china
construct
vhh
phage
display
librari
phage
particl
analyz
elisa
use
recombin
merscov
rbdfc
fc
human
protein
posit
neg
target
protein
respect
screen
rbdspecif
nb
four
round
biopan
one
five
posit
clone
highest
bind
merscov
rbd
select
analys
fig
nb
contain
ctermin
fc
human
respect
construct
base
aforement
vhh
dna
sequenc
encod
synthes
genscript
insert
pichia
pastori
secretori
express
vector
invitrogen
fig
recombin
nbmsfc
express
pichia
pastori
cell
purifi
use
ninta
column
ge
healthcar
protein
sepharos
fast
flow
column
ge
healthcar
respect
purifi
antimerscovrbd
nb
analyz
use
sdspage
western
blot
briefli
nb
load
onto
trisglycin
sdspage
gel
stain
use
coomassi
brilliant
blue
transfer
nitrocellulos
membran
block
overnight
nonfat
milkphosphatebuff
pbst
membran
incub
sequenti
goat
antillama
igg
abcam
horseradish
peroxidas
hrp
conjug
antigoat
igg
r
system
antibodi
h
room
temperatur
ecl
western
blot
substrat
reagent
final
membran
visual
use
amersham
hyperfilm
ge
healthcar
sarscovrbdspecif
mab
use
control
elisa
perform
detect
bind
nb
merscov
rbd
protein
briefli
elisa
plate
coat
overnight
respect
recombin
merscov
rbdfc
rbdfd
one
mutant
rbd
contain
ctermin
human
fc
tag
block
pbst
h
plate
incub
sequenti
serial
dilut
nb
contain
ctermin
fc
tag
either
goat
antillama
mous
antihi
antibodi
sigma
either
hrpconjug
antigoat
igg
hrpconjug
antimous
igg
antibodi
ge
healthcar
h
elisa
substrat
tmb
invitrogen
ad
plate
reaction
stop
n
absorb
nm
measur
use
tecan
infinit
pro
micropl
reader
tecan
detect
bind
nb
denatur
merscov
rbd
protein
elisa
plate
coat
rbdfd
protein
overnight
sequenti
incub
dtt
mm
iodoacetamid
mm
sigma
h
three
wash
use
pbst
elisa
perform
describ
inhibit
bind
merscov
rbd
protein
nb
perform
use
elisa
describ
except
recombin
protein
r
system
serial
dilut
nb
ad
simultan
rbdfccoat
plate
bind
rbd
detect
use
goat
antibodi
r
system
hrpconjug
antigoat
igg
percent
inhibit
calcul
base
valu
bind
presenc
absenc
nb
sarscov
mab
use
neg
control
nb
bind
nb
merscov
rbd
protein
detect
use
instrument
ge
healthcar
previous
describ
briefli
recombin
fcfuse
merscov
rbdfc
protein
nb
captur
use
sensor
chip
protein
ge
healthcar
recombin
merscov
protein
nb
variou
concentr
flown
chip
surfac
run
buffer
contain
mm
hepe
ph
mm
nacl
mm
edta
surfact
sensorgram
analyz
use
biacor
softwar
data
fit
bind
model
assay
perform
detect
inhibit
bind
merscov
rbd
cell
surfac
nb
briefli
cell
express
incub
merscov
rbdfc
protein
min
room
temperatur
absenc
presenc
nb
variou
concentr
cell
incub
fluorescein
isothiocyanatelabel
antihuman
igg
antibodi
sigma
min
analyz
flow
cytometri
percent
inhibit
calcul
base
fluoresc
intens
cell
bind
presenc
absenc
nb
neutral
mer
pseudoviru
entri
nb
perform
previous
describ
briefli
cell
cotransfect
plasmid
encod
envdefect
luciferaseexpress
genom
plasmid
encod
merscov
protein
mer
pseudovirus
harvest
supernat
h
posttransfect
incub
nb
h
ad
cell
h
cell
lyse
cell
lysi
buffer
promega
incub
luciferas
substrat
promega
assay
rel
luciferas
activ
use
tecan
infinit
pro
lumin
tecan
nb
calcul
previous
describ
neutral
merscov
infect
nb
perform
previous
describ
briefli
merscov
strain
amount
equal
median
tissu
cultur
infect
dose
incub
nb
differ
concentr
h
nbviru
mixtur
incub
vero
cell
h
presenc
cytopath
effect
cpe
observ
daili
neutral
activ
nb
report
reedmuench
method
use
calcul
valu
nb
male
femal
mice
week
old
intraven
inject
nb
per
mous
tail
vein
sera
collect
differ
time
point
min
h
h
day
day
day
postinject
concentr
nb
sera
detect
elisa
describ
briefli
merscov
protein
use
coat
elisa
plate
sera
goat
antillama
antibodi
hrpconjug
antigoat
igg
antibodi
sequenti
ad
elisa
reaction
prophylact
therapeut
efficaci
evalu
mice
previous
describ
briefli
male
femal
mice
week
old
intraperiton
anesthet
sodium
pentobarbit
mgkg
bodi
weight
intranas
inocul
lethal
dose
merscov
strain
dulbecco
modifi
eagl
medium
either
day
preinfect
day
postinfect
mice
intraperiton
inject
mgkg
trastuzumab
mab
use
control
nb
infect
mice
observ
daili
day
bodi
weight
surviv
record
statist
analysi
perform
use
graphpad
prism
version
compar
bind
nb
merscov
rbd
protein
well
rbd
without
mutat
receptor
twotail
student
test
use
oneway
analysi
varianc
use
compar
inhibit
nb
bind
statist
signific
surviv
curv
analyz
use
kaplanmei
surviv
analysi
logrank
test
p
valu
lower
consid
statist
signific
figur
indic
p
p
p
respect
data
need
evalu
conclus
present
includ
addit
data
relat
studi
may
request
author
